Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Cleo Diagnostics Limited (ASX:COV) is pleased to announce progress for its U.S. clinical trials in support of its FDA application for its ovarian cancer diagnostic blood test.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to provide the market with an update on activities in the June 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.